Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers

Human Psychopharmacology
Kil-Sang YoonYoung-Chul Chung

Abstract

The present study investigated subjective experiences related to secondary negative symptoms and cognitive performance in healthy volunteers in response to the repeated administration of paliperidone extended-release (ER) and risperidone in a double-blind, placebo-controlled trial. Participants (n = 32) received a fixed dose of one of three study medications for three consecutive days: 6 mg of paliperidone ER, 3 mg of risperidone, or placebo. Subjects were evaluated at baseline and after the first and third administrations of the medications by using the Neuroleptic-Induced Deficit Syndrome Scale and the Scale for the Assessment of Negative Symptoms. Cognitive function was measured at baseline and after the third administration of the medications by using the computerized neuropsychological test. Risperidone was associated with more detrimental subjective experiences compared with paliperidone ER and placebo (p < .05), and these differences persisted after controlling for mental and physical sedation. Analysis of computerized neuropsychological test variables revealed significant differences in the changes in Stroop word-color test results from baseline between the paliperidone ER and risperidone groups (p < .005) and between t...Continue Reading

References

Apr 1, 1978·Archives of General Psychiatry·T Van Putten, P R May
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1993·Schizophrenia Bulletin·A G Awad
Jun 1, 1999·Journal of the International Neuropsychological Society : JINS·S S DikmenN R Temkin
Mar 22, 2000·The Clinical Neuropsychologist·M R BassoJ M Lang
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Oct 4, 2005·The American Journal of Psychiatry·Philip Seeman
Jun 13, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·M TairaK Maeda
Nov 8, 2006·Archives of General Psychiatry·James L ReillyJohn A Sweeney
Feb 16, 2007·Biological Psychiatry·James L ReillyJohn A Sweeney
Jun 12, 2008·International Clinical Psychopharmacology·Carla M CanusoGeorge M Simpson
Oct 1, 2008·Pharmacotherapy·Jehan Marino, Joshua Caballero
Dec 1, 2007·Neuropsychiatric Disease and Treatment·Philip G Janicak, Elizabeth A Winans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here